International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

Urotensin II (UII) is a cyclic neuropeptide that was first isolated from the urophysis of teleost fish on the basis of its ability to contract the hindgut. Subsequently, UII was characterized in tetrapods including humans. Phylogenetic studies and synteny analysis indicate that UII and its paralogous peptide urotensin II-related peptide (URP) belong to the somatostatin/cortistatin superfamily. In mammals, the UII and URP genes are primarily expressed in cholinergic neurons of the brainstem and spinal cord. UII and URP mRNAs are also present in various organs notably in the cardiovascular, renal, and endocrine systems. UII and URP activate a common G protein–coupled receptor, called UT, that exhibits relatively high sequence identity with somatostatin, opioid, and galanin receptors. The UT gene is widely expressed in the central nervous system (CNS) and in peripheral tissues including the retina, heart, vascular bed, lung, kidney, adrenal medulla, and skeletal muscle. Structure-activity relationship studies and NMR conformational analysis have led to the rational design of a number of peptidic and nonpeptidic UT agonists and antagonists. Consistent with the wide distribution of UT, UII has now been shown to exert a large array of biologic activities, in particular in the CNS, the cardiovascular system, and the kidney. Here, we review the current knowledge concerning the pleiotropic actions of UII and discusses the possible use of antagonists for future therapeutic applications.

[1]  D. Johns,et al.  From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. , 2004, Trends in pharmacological sciences.

[2]  D. Chan Cardiovascular and renal effects of urotensins, I and II in the eel, Anguilla rostrata. , 1975, General and comparative endocrinology.

[3]  H. Vaudry,et al.  Divergent cardio-ventilatory and locomotor effects of centrally and peripherally administered urotensin II and urotensin II-related peptides in trout , 2015, Front. Neurosci..

[4]  R. Nishioka,et al.  Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. , 1985, Recent progress in hormone research.

[5]  H. Bern,et al.  Teleostean urophysis: urotensin II and ion transport across the isolated skin of a marine teleost. , 1979, Science.

[6]  M. Clozel,et al.  The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[7]  R. Leduc,et al.  Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. , 2013, Biochemical pharmacology.

[8]  A. Fournier,et al.  Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II , 2008, Peptides.

[9]  Yen-Ling Chen,et al.  Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. , 2008, European journal of pharmacology.

[10]  H. Vaudry,et al.  Urotensin II Peptides , 2013 .

[11]  O. M. Mimura,et al.  Changes in the electrophysiological parameters of the posterior intestine of Anguilla anguilla (Pisces) induced by oxytocin, urotensin II and aldosterone. , 1997, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[12]  H. Schlüter,et al.  Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system , 2003, Analytical and Bioanalytical Chemistry.

[13]  T. Iwanaga,et al.  Immunohistochemical demonstration of urotensins I and II in the caudal neurosecretory system of the Japanese charr,Salvelinus leucomaenis, retained in sea water , 1990 .

[14]  C. Pemberton,et al.  Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury , 2008, Peptides.

[15]  K. Lederis,et al.  Isolation and amino acid sequence of urotensin II from the sturgeon Acipenser ruthenus. , 1992, General and comparative endocrinology.

[16]  K. Lederis Teleost urophysis. II. Biological characterization of the bladder-contracting activity. , 1970, General and comparative endocrinology.

[17]  H. Bern,et al.  Stimulation of sodium transport across the teleost urinary bladder by urotensin II. , 1981, General and comparative endocrinology.

[18]  E. Novellino,et al.  Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. , 2005, Journal of medicinal chemistry.

[19]  U. Hacksell,et al.  Novel potent and efficacious nonpeptidic urotensin II receptor agonists. , 2006, Journal of medicinal chemistry.

[20]  M. Adachi,et al.  Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages , 2005, Hypertension.

[21]  N. Aiyar,et al.  Identification and characterization of binding sites for human urotensin-II in Sprague–Dawley rat renal medulla using quantitative receptor autoradiography , 2006, Peptides.

[22]  Xiaokun Li,et al.  Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. , 2008, American journal of physiology. Endocrinology and metabolism.

[23]  M. Shichiri,et al.  Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues , 2001, Journal of hypertension.

[24]  D. Guidolin,et al.  Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations , 2009, Regulatory Peptides.

[25]  H. Krum,et al.  Cardiovascular role of urotensin II: effect of chronic infusion in the rat , 2004, Peptides.

[26]  H. Vaudry,et al.  Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. , 2004, European journal of endocrinology.

[27]  R. Nishioka,et al.  Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Nothacker,et al.  From heart to mind , 2005 .

[29]  A. Balat,et al.  Urotensin-II Immunoreactivity in Children with Chronic Glomerulonephritis , 2007, Renal failure.

[30]  T. Yoshimoto,et al.  Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. , 2003, Endocrinology.

[31]  H. Vaudry,et al.  Spasmogenic actions of frog urotensin II on the bladder and ileum of the frog, Rana catesbeiana. , 1994, General and comparative endocrinology.

[32]  H. Vaudry,et al.  Cardiovascular actions of frog urotensin II in the frog, Rana catesbeiana. , 1995, General and comparative endocrinology.

[33]  M. Létourneau,et al.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design , 2012, Front. Endocrin..

[34]  T. Kox,et al.  The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease , 2004, Regulatory Peptides.

[35]  S. Douglas,et al.  Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. , 2006, Journal of molecular and cellular cardiology.

[36]  E. Novellino,et al.  Urotensin-II receptor ligands. From agonist to antagonist activity. , 2005, Journal of medicinal chemistry.

[37]  H. Vaudry,et al.  Structure–activity relationships of urotensin II and URP , 2008, Peptides.

[38]  E. Novellino,et al.  Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells , 2011, Journal of cellular biochemistry.

[39]  J. E. Vaughn,et al.  Generation patterns of four groups of cholinergic neurons in rat cervical spinal cord: A combined tritiated thymidine autoradiographic and choline acetyltransferase immunocytochemical study , 1988, The Journal of comparative neurology.

[40]  H. Vaudry,et al.  Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout Oncorhynchus mykiss , 2004, Brain Research.

[41]  Nobuyuki Miyajima,et al.  Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. , 2003, Biochemical and biophysical research communications.

[42]  T. Smani,et al.  Association Analysis of Urotensin II Gene (UTS2) and Flanking Regions with Biochemical Parameters Related to Insulin Resistance , 2011, PloS one.

[43]  S. Douglas,et al.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. , 2000, Trends in cardiovascular medicine.

[44]  A. Davenport,et al.  Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function , 2008, Peptides.

[45]  H. Vaudry,et al.  [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes , 2008, Peptides.

[46]  P. Pacaud,et al.  UT Receptor-Expressing Monocytes Urotensin II is a New Chemotactic Factor for and , 2007 .

[47]  S. Douglas,et al.  Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[48]  N. Seidah,et al.  The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions* , 2013, The Journal of Biological Chemistry.

[49]  R. Nishioka,et al.  Effects of somatostatin and urotensin II on tilapia pituitary prolactin release and interactions between somatostatin, osmotic pressure Ca++, and adenosine 3',5'-monophosphate in prolactin release in vitro. , 1982, Endocrinology.

[50]  Yong Zhang,et al.  The evolution of somatostatin in vertebrates. , 2010, Gene.

[51]  Pierre Renard,et al.  Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction , 2003, Journal of enzyme inhibition and medicinal chemistry.

[52]  Ettore Novellino,et al.  Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues. , 2002, Bioorganic & medicinal chemistry.

[53]  R. Balment,et al.  Peptide hormones influence in vitro interrenal secretion of cortisol in the trout, Oncorhynchus mykiss. , 1994, General and comparative endocrinology.

[54]  S. Douglas,et al.  Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat , 2000, British journal of pharmacology.

[55]  H. Nothacker,et al.  Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. , 2000, European journal of pharmacology.

[56]  Z. Ao,et al.  Urotensin II and renal function in the rat. , 2006, Kidney international.

[57]  D. Guidolin,et al.  The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways , 2010, Regulatory Peptides.

[58]  S. Ito,et al.  Increased plasma urotensin II levels in patients with diabetes mellitus. , 2003, Clinical science.

[59]  E. Kostenis,et al.  Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[60]  H. Heng,et al.  Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. , 1995, Genomics.

[61]  D. Behm,et al.  Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[62]  N. Ashton,et al.  Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II. , 2008, American journal of physiology. Renal physiology.

[63]  A. Gibson Complex effects of Gillichthys urotensin II on rat aortic strips , 1987, British journal of pharmacology.

[64]  J. Ketelslegers,et al.  Circulating urotensin II levels in moderate to severe congestive heart failure: Its relations with myocardial function and well established neurohormonal markers , 2006, Peptides.

[65]  Y. Zou,et al.  Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats , 2001, FEBS letters.

[66]  D. Lambert,et al.  Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study. , 2005, British Journal of Anaesthesia.

[67]  David G. Behm,et al.  Urotensin II Receptor Knockout Mice on an ApoE Knockout Background Fed a High-Fat Diet Exhibit an Enhanced Hyperlipidemic and Atherosclerotic Phenotype , 2009, Circulation research.

[68]  H. Vaudry,et al.  Central and peripheral cardiovascular, ventilatory, and motor effects of trout urotensin-II in the trout , 2008, Peptides.

[69]  E. Novellino,et al.  Endogenous Urotensin II Selectively Modulates Erectile Function through eNOS , 2012, PloS one.

[70]  D. Chan,et al.  Pharmacological effects of urotensins. I. Regional vascular effects of urotensins I and II in the rat. , 1975, Pharmacology.

[71]  R. Silvestre,et al.  Inhibition of Insulin Release by Urotensin II - A Study on the Perfused Rat Pancreas , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[72]  G. Sharp Mechanisms of inhibition of insulin release. , 1996, The American journal of physiology.

[73]  D. Lambert,et al.  Role of urotensin II and its receptor in health and disease , 2007, Journal of Anesthesia.

[74]  M. Kawata,et al.  Urotensin II-immunoreactive neurons in the caudal neurosecretory system of freshwater and seawater fish , 2004, Cell and Tissue Research.

[75]  R. Bayraktar,et al.  Association Between Thr21Met and Ser89Asn Polymorphisms of the Urotensin II Gene and Systemic Sclerosis , 2012, Journal of Rheumatology.

[76]  B. Cheung,et al.  The role of urotensin II in the metabolic syndrome , 2008, Peptides.

[77]  Baofeng Yang,et al.  Downregulation of miR-21 is involved in direct actions of ursolic acid on the heart: implications for cardiac fibrosis and hypertrophy. , 2015, Cardiovascular therapeutics.

[78]  H. Krum,et al.  Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure , 2004, Circulation.

[79]  M. Adachi,et al.  Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. , 2008, Clinical science.

[80]  R. Nishioka,et al.  In vitro effects of somatostatin and urotensin II on prolactin and growth hormone secretion in tilapia, Oreochromis mossambicus. , 1986, General and comparative endocrinology.

[81]  Jian Jin Aminoalkoxybenzyl Pyrrolidines as Novel Human Urotensin‐II Receptor Antagonists. , 2005 .

[82]  H. Krum,et al.  Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[83]  J. Bertoglio,et al.  Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase , 2001, Circulation research.

[84]  Nancy S. Magnuson,et al.  Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus , 2008, International journal of biological sciences.

[85]  M. Iida,et al.  Central cardiovascular action of urotensin II in conscious rats , 2003, Journal of hypertension.

[86]  M. Marcoli,et al.  Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals , 2010, Neuroscience.

[87]  A. Clerk,et al.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis , 2008, British journal of pharmacology.

[88]  O. Prospero-Garcia,et al.  A cortical neuropeptide with neuronal depressant and sleep-modulating properties , 1996, Nature.

[89]  H. Vaudry,et al.  Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda. , 1992, Biochemical and biophysical research communications.

[90]  C. May,et al.  Effect of central urotensin II on heart rate, blood pressure and brain Fos immunoreactivity in conscious rats , 2008, Neuroscience.

[91]  G. Moore,et al.  Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. , 1982, Science.

[92]  N. Doucet,et al.  Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists. , 2013, Journal of medicinal chemistry.

[93]  R. Elde,et al.  Immunohistochemical localization of urotensin I/corticotropin‐releasing factor, urotensin II, and serotonin immunoreactivities in the caudal spinal cord of nonteleost fishes , 1986, The Journal of comparative neurology.

[94]  B. Vígh,et al.  Actual problems of the cerebrospinal fluid‐contacting neurons , 1998, Microscopy research and technique.

[95]  L. Ji,et al.  [The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population]. , 2002, Zhonghua yi xue za zhi.

[96]  P. Molenaar,et al.  Cardiovascular actions of human urotensin II—considerations for hypertension , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[97]  J. Fabiani,et al.  Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin‐II , 2001, Fundamental & clinical pharmacology.

[98]  A. Fassina,et al.  Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism. , 2009, The Journal of clinical endocrinology and metabolism.

[99]  J. Parys,et al.  Inositol 1,4,5-trisphosphate and its receptors. , 2012, Advances in experimental medicine and biology.

[100]  D. Lambert,et al.  A Comparison of Cerebrospinal Fluid and Plasma Urotensin II Concentrations in Normotensive and Hypertensive Patients Undergoing Urological Surgery During Spinal Anesthesia: A Pilot Study , 2003, Anesthesia and analgesia.

[101]  E. Novellino,et al.  Urotensin‐II receptor peptide agonists , 2004, Medicinal research reviews.

[102]  R. Hannan,et al.  Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. , 2004, Molecular endocrinology.

[103]  E. Mackenzie,et al.  Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats , 2008, Experimental Neurology.

[104]  F. Russell Urotensin II in cardiovascular regulation , 2008, Vascular health and risk management.

[105]  Y. Takei,et al.  Potent cardiovascular effects of homologous urotensin II (UII)-related peptide and UII in unanesthetized eels after peripheral and central injections. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[106]  J. Rivier,et al.  Characterization of the biologically and antigenically important regions of urotensin II. , 1986, Proceedings of the Western Pharmacology Society.

[107]  H. Auer,et al.  Transcriptional profiling of the megabladder mouse: A unique model of bladder dysmorphogenesis , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[108]  S. Krähenbühl,et al.  Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients , 2006, Clinical pharmacology and therapeutics.

[109]  N. Dun,et al.  State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells , 2008, Peptides.

[110]  S. Douglas,et al.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4–11) (UFP‐803) , 2006, British journal of pharmacology.

[111]  P. Rorsman,et al.  Suppression of insulin release by galanin and somatostatin is mediated by a G-protein. An effect involving repolarization and reduction in cytoplasmic free Ca2+ concentration. , 1989, The Journal of biological chemistry.

[112]  J. Conlon,et al.  Brain neuropeptides in central ventilatory and cardiovascular regulation in trout , 2012, Front. Endocrin..

[113]  Chao-shu Tang,et al.  Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium , 2002, Heart and Vessels.

[114]  T. Deguchi,et al.  Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-alpha and -gamma , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[115]  D. Thompson,et al.  A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. , 1995, Biochemical and biophysical research communications.

[116]  R. Balment,et al.  Native urotensins influence cortisol secretion and plasma cortisol concentration in the euryhaline flounder, platichthys flesus. , 1998, General and comparative endocrinology.

[117]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[118]  R. Silvestre,et al.  Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat. , 1986, Biochemical and biophysical research communications.

[119]  J. Botting,et al.  Neuropeptide-induced contraction and relaxation of the mouse anococcygeus muscle. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[120]  Xue-mei Ma,et al.  Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. , 2010, International journal of molecular medicine.

[121]  T. Dschietzig,et al.  Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure , 2002, Regulatory Peptides.

[122]  H. Yoshimatsu,et al.  Intracerebroventricular administration of urotensin II regulates food intake and sympathetic nerve activity in brown adipose tissue , 2012, Peptides.

[123]  H. Nothacker,et al.  From heart to mind. The urotensin II system and its evolving neurophysiological role. , 2005, The FEBS journal.

[124]  Jana Sopkova-de Oliveira Santos,et al.  Definition of New Pharmacophores for Nonpeptide Antagonists of Human Urotensin‐II. Comparison with the 3D‐Structure of Human Urotensin‐II and URP. , 2007 .

[125]  R. Leduc,et al.  Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. , 2009, Biochemical pharmacology.

[126]  R. Silvestre,et al.  Evidence for endogenous urotensin-II as an inhibitor of insulin secretion Study in the perfused rat pancreas , 2008, Peptides.

[127]  Peter Hess,et al.  Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists , 1984, Nature.

[128]  L. Lecea,et al.  Neuropeptide interactions and REM sleep: A role for Urotensin II? , 2008, Peptides.

[129]  N. Hazon,et al.  Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. , 1996, The Journal of experimental zoology.

[130]  S. Douglas,et al.  Human urotensin‐II is a potent spasmogen of primate airway smooth muscle , 2000, British journal of pharmacology.

[131]  H. Vaudry,et al.  Cardiovascular actions of trout urotensin II in the conscious trout, Oncorhynchus mykiss. , 1996, The American journal of physiology.

[132]  S. Opal,et al.  Proprotein convertases in health and disease. , 2011, The New England journal of medicine.

[133]  J. Mee The synergistic effect , 1965 .

[134]  I. Muramatsu,et al.  Effects of Urotensins on the Cardiovascular System of a Teleost Fish and a Bird , 1979 .

[135]  Ethan S. Burstein,et al.  Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). , 2002 .

[136]  J. Taxi,et al.  Caudal neurosecretory system of the zebrafish: ultrastructural organization and immunocytochemical detection of urotensins , 2006, Cell and Tissue Research.

[137]  H. Bern,et al.  The influence of urotensin II on calcium flux in rat aorta , 1988, The Journal of pharmacy and pharmacology.

[138]  J J Quattrochi,et al.  Mapping neuronal inputs to REM sleep induction sites with carbachol-fluorescent microspheres. , 1989, Science.

[139]  J. Jing,et al.  Urotensin II in Invertebrates: From Structure to Function in Aplysia californica , 2012, PloS one.

[140]  S. Douglas,et al.  Congestive heart failure and expression of myocardial urotensin II , 2002, The Lancet.

[141]  A. Calas,et al.  Urotensin-II expression in the mouse spinal cord , 2006, Journal of Chemical Neuroanatomy.

[142]  Xiaojing Yu,et al.  The involvement of transforming growth factor-β1 secretion in Urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts , 2007, Regulatory Peptides.

[143]  S. Rault,et al.  Nonpeptide Urotensin-II receptor agonists and antagonists: Review and structure–activity relationships , 2008, Peptides.

[144]  M. Létourneau,et al.  Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. , 2012, Biochemical pharmacology.

[145]  F. Leslie,et al.  The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat , 2001, Brain Research.

[146]  J. Conlon,et al.  Post‐translational processing of prepro‐urotensin II , 1990, FEBS letters.

[147]  A. Fournier,et al.  Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide. , 2006, Biochemistry.

[148]  N. Colloc'h,et al.  Three‐dimensional model of the human urotensin‐II receptor: Docking of human urotensin‐II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model , 2008, Proteins.

[149]  H. Narayan,et al.  The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure , 2013, Peptides.

[150]  K. Lukowiak,et al.  Distribution and coexistence of urotensin I and urotensin II peptides in the cerebral ganglia of Aplysia californica , 1992, Peptides.

[151]  H. Vaudry,et al.  Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors , 1999, FEBS letters.

[152]  Chao-shu Tang,et al.  Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol , 2007, Acta Pharmacologica Sinica.

[153]  Christophe D. Proulx,et al.  Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites. , 2007, The Biochemical journal.

[154]  K. Takekoshi,et al.  Effect of Urotensin II on PC12 Rat Pheochromocytoma Cells , 2010, Journal of neuroendocrinology.

[155]  A. Davenport,et al.  Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats , 2001, British journal of pharmacology.

[156]  W. Frishman,et al.  Urotensin II: A New Pharmacologic Target in the Treatment of Cardiovascular Disease , 2008, Cardiology in review.

[157]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[158]  H. Vaudry,et al.  Biochemical and functional characterization of high‐affinity urotensin II receptors in rat cortical astrocytes , 2006, Journal of neurochemistry.

[159]  F. Lammert,et al.  Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats , 2007, Hepatology.

[160]  J. Stasch,et al.  Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. , 2004, International journal of cardiology.

[161]  Jilly F. Evans,et al.  Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. , 1999, Biochemical and biophysical research communications.

[162]  H. Bern,et al.  Active chloride transport by the skin of a marine teleost is stimulated by urotensin I and inhibited by urotensin II. , 1981, General and comparative endocrinology.

[163]  R. Kirchmair,et al.  Secretoneurin—a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C) , 1993, Neuroscience.

[164]  I. Komuro,et al.  Urotensin II inhibits the proliferation but not the differentiation of cardiac side population cells , 2011, Peptides.

[165]  J. Conlon,et al.  Antimicrobial peptides from the skins of North American frogs. , 2009, Biochimica et biophysica acta.

[166]  J. Taylor,et al.  Structural requirements at the N-terminus of urotensin II octapeptides , 2002, Peptides.

[167]  H. Vaudry,et al.  Somatostatin- and urotensin II-related peptides: molecular diversity and evolutionary perspectives , 1997, Regulatory Peptides.

[168]  Yi-Zhun Zhu,et al.  Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. , 2007, American journal of physiology. Heart and circulatory physiology.

[169]  I. Wilkinson,et al.  The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. , 2009, British journal of clinical pharmacology.

[170]  K. Asayama,et al.  Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure , 2008, Peptides.

[171]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .

[172]  F. Vandesande,et al.  Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[173]  I. Toth,et al.  Urotensin-II-Converting Enzyme Activity of Furin and Trypsin in Human Cells in Vitro , 2004, Journal of Pharmacology and Experimental Therapeutics.

[174]  H. Bern,et al.  Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. , 1987, General and comparative endocrinology.

[175]  Hassan Oulyadi,et al.  Structure–activity relationships and structural conformation of a novel urotensin II-related peptide , 2004, Peptides.

[176]  K. Hyndman,et al.  Urotensin II and its receptor in the killifish gill: regulators of NaCl extrusion , 2011, Journal of Experimental Biology.

[177]  Yi-Zhun Zhu,et al.  Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. , 2004, Journal of applied physiology.

[178]  R. Pakala Role of urotensin II in atherosclerotic cardiovascular diseases. , 2008, Cardiovascular revascularization medicine : including molecular interventions.

[179]  L. Bertrand,et al.  Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3β signaling pathway , 2010, Peptides.

[180]  T. Klabunde,et al.  Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay , 2003, Journal of Pharmacology and Experimental Therapeutics.

[181]  S. Hadjadj,et al.  Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy , 2010, Hypertension.

[182]  S. Katz Mechanisms and implications of endothelial dysfunction in congestive heart failure. , 1997, Current opinion in cardiology.

[183]  K. Shimada,et al.  Gene expression in the adrenal glands of three spontaneously hypertensive rat substrains. , 2010, Molecular medicine reports.

[184]  I. Wakabayashi,et al.  Mechanism of human urotensin II-induced contraction in rat aorta. , 2004, Journal of pharmacological sciences.

[185]  J. Qi,et al.  Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors , 2005, Peptides.

[186]  A. Richards,et al.  Plasma urotensin II in heart failure , 2002, The Lancet.

[187]  S. Ito,et al.  Role of urotensin II in patients on dialysis , 2001, The Lancet.

[188]  H. Vaudry,et al.  Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord , 2005, Neuroscience.

[189]  M. Grabowski,et al.  Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension. , 2006, International journal of cardiology.

[190]  Jérôme Leprince,et al.  Urotensin II, from fish to human , 2010, Annals of the New York Academy of Sciences.

[191]  N. Hazon,et al.  Cardiovascular actions of dogfish urotensin II in the dogfish Scyliorhinus canicula. , 1993, The American journal of physiology.

[192]  H. Vaudry,et al.  Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord , 2002, Neuroscience.

[193]  Ralph Hirschmann,et al.  Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor. , 2006, Organic letters.

[194]  E. Kostenis,et al.  A new ligand for the urotensin II receptor , 2002, British journal of pharmacology.

[195]  C. Kitada,et al.  Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents , 2004, Neuroscience Letters.

[196]  David G. Behm,et al.  Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist , 2002, British journal of pharmacology.

[197]  H. Vaudry,et al.  New insight into the molecular evolution of the somatostatin family , 2008, Molecular and Cellular Endocrinology.

[198]  A. Kristof,et al.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis , 2010, Peptides.

[199]  A. Y. Chiu,et al.  Early stages in the development of spinal motor neurons , 1992, The Journal of comparative neurology.

[200]  Kazuhiro Takahashi,et al.  Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure , 2009, Peptides.

[201]  H. Vaudry,et al.  Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord , 2004, Journal of neurochemistry.

[202]  H. Vaudry,et al.  Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[203]  D. Webb,et al.  High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. , 2002, Cardiovascular research.

[204]  J. McMurray,et al.  Effects of Urotensin II in Human Arteries and Veins of Varying Caliber , 2001, Circulation.

[205]  M. Miyazato,et al.  Urotensin II receptor (UTR) exists in hyaline chondrocytes: a study of peripheral distribution of UTR in the African clawed frog, Xenopus laevis. , 2013, General and comparative endocrinology.

[206]  G. Thanassoulis,et al.  Urotensin II and cardiovascular diseases , 2004, Peptides.

[207]  C. Mccrohan,et al.  Fish caudal neurosecretory system: a model for the study of neuroendocrine secretion. , 2007, General and comparative endocrinology.

[208]  David G. Behm,et al.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes , 2013, Diabetologia.

[209]  H. Dai,et al.  Urotensin‐2 promotes collagen synthesis via ERK1/2‐dependent and ERK1/2‐independent TGF‐β1 in neonatal cardiac fibroblasts , 2011, Cell biology international.

[210]  D. Behm,et al.  Urotensin-II: a novel systemic hypertensive factor in the cat , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[211]  H. Vaudry,et al.  Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. , 2006, Journal of medicinal chemistry.

[212]  S. Ito,et al.  Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues , 2008, Peptides.

[213]  H. Bern,et al.  The isolated trout rectum bioassay for urotensin II: assessment for specificity and precision. , 1978, General and comparative endocrinology.

[214]  H. Bern,et al.  THE UROPHYSIS AND THE CAUDAL NEUROSECRETORY SYSTEM OF FISHES , 1968, Biological reviews of the Cambridge Philosophical Society.

[215]  M. Ichinose,et al.  Potentiation of GABAA receptor‐mediated Cl‐ current by urotensin peptides in identified Aplysia neurons , 1999, Journal of neuroscience research.

[216]  C. May,et al.  Cardiac actions of central but not peripheral urotensin II are prevented by β-adrenoceptor blockade , 2005, Peptides.

[217]  B. Gogebakan,et al.  Association Between Thr21Met and Ser89Asn Polymorphisms of the Urotensin-II (UTS2) Gene, Diabetes Mellitus, and Diabetic Retinopathy , 2012, Current eye research.

[218]  S. Salvadori,et al.  Urotensin II stimulates plasma extravasation in mice via UT receptor activation , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[219]  M Kurihara,et al.  Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). , 1999, Biochemical and biophysical research communications.

[220]  H. Vaudry,et al.  Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts , 2006, Peptides.

[221]  Kazuhiro Takahashi,et al.  Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II , 2003, Peptides.

[222]  H. Krum,et al.  Therapeutic potential of blockade of the Urotensin II system in systemic hypertension , 2007, Current hypertension reports.

[223]  R. Silvestre,et al.  Characterization of the insulinostatic effect of urotensin II: A study in the perfused rat pancreas , 2009, Regulatory Peptides.

[224]  C. May,et al.  Urotensin II, a novel peptide in central and peripheral cardiovascular control , 2004, Peptides.

[225]  J A Hobson,et al.  Microinjection of neostigmine into the pontine reticular formation of cats enhances desynchronized sleep signs. , 1984, The Journal of pharmacology and experimental therapeutics.

[226]  S. L. Dun,et al.  Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat , 2001, Neuroscience Letters.

[227]  J. Hagan,et al.  Central effects of urotensin-II following ICV administration in rats , 2001, Psychopharmacology.

[228]  I. Toth,et al.  Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. , 2003, American journal of physiology. Heart and circulatory physiology.

[229]  A Fournier,et al.  Discovery of new antagonists aimed at discriminating UII and URP‐mediated biological activities: insight into UII and URP receptor activation , 2013, British journal of pharmacology.

[230]  R. Jones,et al.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries , 2004, Thorax.

[231]  C. Loretz Recognition by goby intestine of a somatostatin analog, SMS 201-995. , 1990, The Journal of experimental zoology. Supplement : published under auspices of the American Society of Zoologists and the Division of Comparative Physiology and Biochemistry.

[232]  P. Gilon,et al.  Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. , 2001, Endocrine reviews.

[233]  N. Xie,et al.  Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[234]  S. Salvadori,et al.  Structure–activity relationship study on Tyr9 of urotensin-II(4–11): Identification of a partial agonist of the UT receptor , 2009, Peptides.

[235]  Yan Shen,et al.  [The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China]. , 2002, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[236]  A. Davenport,et al.  Urotensin II: fish neuropeptide catches orphan receptor. , 2000, Trends in pharmacological sciences.

[237]  S. Douglas,et al.  Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. , 2001, American journal of physiology. Heart and circulatory physiology.

[238]  E. Novellino,et al.  A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. , 2002, Journal of medicinal chemistry.

[239]  C. May,et al.  Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions , 2003, Hypertension.

[240]  T. Ichikawa The caudal neurosecretory system of fishes , 1986 .

[241]  Chao-shu Tang,et al.  Cardiovascular effects of urotensin II in different brain areas , 2002, Peptides.

[242]  Kazuhiro Takahashi,et al.  Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells , 2001, Peptides.

[243]  N. Aiyar,et al.  Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines , 2004, British journal of pharmacology.

[244]  H. Kawauchi,et al.  Characterization of melanin-concentrating hormone in chum salmon pituitaries , 1983, Nature.

[245]  H. Bern,et al.  Cardiovascular effects of urotensin II in anesthetized and pithed rats. , 1986, General and comparative endocrinology.

[246]  Wayne A. Decatur,et al.  Insight from the lamprey genome: glimpsing early vertebrate development via neuroendocrine-associated genes and shared synteny of gonadotropin-releasing hormone (GnRH). , 2013, General and comparative endocrinology.

[247]  L. Heinemann,et al.  Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. , 2009, British journal of clinical pharmacology.

[248]  H. Krum,et al.  Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy , 2003, Circulation research.

[249]  E. Novellino,et al.  Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta , 2003, British journal of pharmacology.

[250]  Urotensin II acts as a modulator of mesopontine cholinergic neurons , 2005, Brain Research.

[251]  H. Vaudry,et al.  Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization , 1996, The Journal of comparative neurology.

[252]  M. Iida,et al.  Central cardiovascular action of urotensin II in spontaneously hypertensive rats. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[253]  E. Novellino,et al.  Urotensin-II receptor antagonists. , 2006, Current medicinal chemistry.

[254]  J. Joly,et al.  Molecular evolution of peptidergic signaling systems in bilaterians , 2013, Proceedings of the National Academy of Sciences.

[255]  S. Salvadori,et al.  Structure–activity relationship study on human urotensin II , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[256]  H. Sarau,et al.  Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.

[257]  J. Pernow,et al.  Urotensin II evokes potent vasoconstriction in humans in vivo , 2002, British journal of pharmacology.

[258]  H. Krum,et al.  Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. , 2004, Current opinion in investigational drugs.

[259]  H. Itoh,et al.  Functional receptors for fish neuropeptide urotensin II in major rat arteries. , 1988, European journal of pharmacology.

[260]  T. Katagiri,et al.  Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. , 2001 .

[261]  S. Douglas,et al.  Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease , 2006, Peptides.

[262]  U. Dahlgren THE ELECTRIC MOTOR NERVE CENTERS IN THE SKATES (RAJIDAe). , 1914, Science.

[263]  G. Albertin,et al.  Urotensin-II and UII-receptor expression and function in the rat adrenal cortex. , 2006, International journal of molecular medicine.

[264]  P. Pacaud,et al.  Urotensin II and atherosclerosis , 2008, Peptides.

[265]  J. Pfeilschifter,et al.  Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[266]  J. Conlon “Liberation” of urotensin II from the teleost urophysis: An historical overview , 2008, Peptides.

[267]  Michele Caraglia,et al.  Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures , 2013, Journal of amino acids.

[268]  R. Nishioka,et al.  The Caudal Neurosecretory System and Osmoregulation , 1979 .

[269]  H. Vaudry,et al.  Behavioral actions of urotensin-II , 2008, Peptides.

[270]  D. Behm,et al.  Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. , 2004, European journal of pharmacology.

[271]  H. Hamm,et al.  Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. , 2013, Journal of molecular biology.

[272]  D. Lambert,et al.  Desensitisation of native and recombinant human urotensin-II receptors , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

[273]  Dan Larhammar,et al.  Molecular evolution of GPCRs: Somatostatin/urotensin II receptors. , 2014, Journal of molecular endocrinology.

[274]  G. Liapakis,et al.  Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors. , 2002, Methods in enzymology.

[275]  Isabelle Lihrmann,et al.  Impact of gene/genome duplications on the evolution of the urotensin II and somatostatin families. , 2013, General and comparative endocrinology.

[276]  N. Ashton,et al.  Urotensin II: lessons from comparative studies for general endocrinology. , 2008, General and comparative endocrinology.

[277]  Ravinder Abrol,et al.  Prediction of the Three‐Dimensional Structure for the Rat Urotensin II Receptor, and Comparison of the Antagonist Binding Sites and Binding Selectivity between Human and Rat Receptors from Atomistic Simulations , 2010, ChemMedChem.

[278]  R. Hannan,et al.  Urotensin II: the old kid in town , 2004, Trends in Endocrinology & Metabolism.

[279]  H. Yoshida,et al.  Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome. , 2009, Atherosclerosis.

[280]  Hélène Castel,et al.  The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. , 2010, The Biochemical journal.

[281]  You-Qiang Song,et al.  Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance , 2006, Peptides.

[282]  E. Novellino,et al.  Urotensin II: a novel target in human corpus cavernosum. , 2010, The journal of sexual medicine.

[283]  Junnian Zheng,et al.  Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo. , 2010, Oncology reports.

[284]  D. Guidolin,et al.  Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. , 2006, International journal of molecular medicine.

[285]  N. Aiyar,et al.  Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[286]  F. Russell Emerging roles of urotensin-II in cardiovascular disease. , 2004, Pharmacology & therapeutics.

[287]  E. Tutar,et al.  Urotensin Inhibition with Palosuran Could Be a Promising Alternative in Pulmonary Arterial Hypertension , 2013, Inflammation.

[288]  Yen-Ling Chen,et al.  Urotensin II-induced endothelin-1 expression and cell proliferation via epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. , 2009, Atherosclerosis.

[289]  David G. Behm,et al.  Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375 , 2005, British journal of pharmacology.

[290]  Takeshi Saito,et al.  Contraction of isolated guinea-pig ileum by urotensin II via activation of ganglionic cholinergic neurons and acetylcholine release , 2003, Neuropharmacology.

[291]  N. Ashton,et al.  The Urotensin System Is Up-Regulated in the Pre-Hypertensive Spontaneously Hypertensive Rat , 2013, PloS one.

[292]  M. Sugawara,et al.  Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. , 2001, Journal of the American College of Cardiology.

[293]  N. Aiyar,et al.  Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey , 2002, British journal of pharmacology.

[294]  M. Kikuya,et al.  Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: Comparison with endothelin-1 , 2009, Peptides.

[295]  Cheng-Hsien Chen,et al.  Urotensin II Induces Rat Cardiomyocyte Hypertrophy via the Transient Oxidization of Src Homology 2-Containing Tyrosine Phosphatase and Transactivation of Epidermal Growth Factor Receptor , 2009, Molecular Pharmacology.

[296]  A. Velic,et al.  Ligands and Signaling of the G-Protein-Coupled Receptor GPR14, Expressed in Human Kidney Cells , 2006, Cellular Physiology and Biochemistry.

[297]  H. Krum,et al.  Urotensin II: a new player in vascular and myocardial disease? , 2003, Clinical science.

[298]  C. Loretz,et al.  Ion transport in goby intestine: cellular mechanism of urotensin II stimulation. , 1985, The American journal of physiology.

[299]  H. Vaudry,et al.  Characterization of urotensin II, distribution of urotensin II, urotensin II‐related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction , 2008, Journal of neurochemistry.

[300]  S. Miyano,et al.  Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator , 2004, FEBS letters.

[301]  Xiao‐xing Yin,et al.  Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice. , 2012, Oncology letters.

[302]  H. Vaudry,et al.  Isolation of [Pro2,Met13]somatostatin-14 and somatostatin-14 from the frog brain reveals the existence of a somatostatin gene family in a tetrapod. , 1992, Biochemical and biophysical research communications.

[303]  M. Clozel,et al.  Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System , 2004, Journal of Pharmacology and Experimental Therapeutics.

[304]  Patricia Andrade-Gordon,et al.  Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. , 2002, Angewandte Chemie.

[305]  Benjamin D. Hunt,et al.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[306]  J. Rivier,et al.  Contraction of major artery segments of rat by fish neuropeptide urotensin II. , 1987, The American journal of physiology.

[307]  H. Vaudry,et al.  Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5 , 2008, Peptides.

[308]  Urotensin II evokes neurotransmitter release from rat cerebrocortical slices , 2008, Neuroscience Letters.

[309]  Yu-guang Li,et al.  Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta , 2008, Journal of hypertension.

[310]  N. Dun,et al.  The vasoactive peptide urotensin II stimulates spontaneous release from frog motor nerve terminals , 2003, British journal of pharmacology.

[311]  Yuan Zhang,et al.  Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[312]  P. Poulin,et al.  Radioimmunoassays for fish tail neuropeptides: II. Development of a specific and sensitive assay for and the occurrence of immunoreactive urotensin II in the central nervous system and blood of Catostomus commersoni. , 1986, Journal of pharmacological methods.

[313]  Yahong Chen,et al.  The signal transduction pathway in the proliferation of airway smooth muscle cells induced by urotensin II. , 2004, Chinese medical journal.

[314]  T. Katagiri,et al.  Synergistic Effect of Urotensin II With Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells , 2001, Circulation.

[315]  U. Hacksell,et al.  Isochromanone-based urotensin-II receptor agonists. , 2005, Bioorganic & medicinal chemistry.

[316]  Y. Hinokio,et al.  Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects , 2003, Diabetologia.

[317]  H. Tostivint,et al.  Characterization of the true ortholog of the urotensin II-related peptide (URP) gene in teleosts. , 2012, General and comparative endocrinology.

[318]  N. Dun,et al.  Urotensin‐II regulates intracellular calcium in dissociated rat spinal cord neurons , 2002, Journal of neurochemistry.

[319]  N. Hazon,et al.  Purification and characterization of urotensin II and parvalbumin from an elasmobranch fish, Scyliorhinus canicula (common dogfish). , 1992, Neuroendocrinology.

[320]  B. Cheung,et al.  Plasma concentration of urotensin II is raised in hypertension , 2004, Journal of hypertension.

[321]  M. Kikuchi,et al.  A novel avian hypothalamic peptide inhibiting gonadotropin release. , 2000, Biochemical and biophysical research communications.

[322]  A. Ishihata,et al.  Vascular contractile effect of urotensin II in young and aged rats: Influence of aging and contribution of endothelial nitric oxide , 2006, Peptides.

[323]  B. Maryanoff,et al.  Urotensin-II receptor modulators as potential drugs. , 2010, Journal of medicinal chemistry.

[324]  E. Novellino,et al.  New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide. , 2009, Journal of medicinal chemistry.

[325]  J. Conlon Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research , 2000, Regulatory Peptides.

[326]  Jun Wang,et al.  Genomic Diversity and Evolution of the Head Crest in the Rock Pigeon , 2013, Science.

[327]  Dong-mei Liu,et al.  The Effects of Urotensin‐II on Proliferation of Pheochromocytoma Cells and mRNA Expression of Urotensin‐II and Its Receptor in Pheochromocytoma Tissues , 2006, Annals of the New York Academy of Sciences.

[328]  H. Sarau,et al.  The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems , 2006, British journal of pharmacology.

[329]  A. Giaid,et al.  Potential Clinical Implications of the Urotensin II Receptor Antagonists , 2011, Front. Pharmacol..

[330]  U. Hacksell,et al.  Novel and potent small-molecule urotensin II receptor agonists. , 2009, Bioorganic & medicinal chemistry.

[331]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[332]  A. Richards,et al.  Urotensin II: Evidence for cardiac, hepatic and renal production , 2005, Peptides.

[333]  K. Lederis,et al.  Isolation and amino acid sequence of two urotensin II peptides from Catostomus Commersoni urophyses , 1983, Peptides.

[334]  I. Squire,et al.  Plasma Urotensin in Human Systolic Heart Failure , 2002, Circulation.

[335]  G. Gray,et al.  Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. , 2001, Life sciences.

[336]  C. Mccrohan,et al.  Molecular characterization and expression of urotensin II and its receptor in the flounder (Platichthys flesus): a hormone system supporting body fluid homeostasis in euryhaline fish. , 2006, Endocrinology.

[337]  S. Henriksen,et al.  Urotensin II Modulates Rapid Eye Movement Sleep through Activation of Brainstem Cholinergic Neurons , 2005, The Journal of Neuroscience.

[338]  H. Sarau,et al.  The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors , 2003, British journal of pharmacology.

[339]  S. Brunak,et al.  SignalP 4.0: discriminating signal peptides from transmembrane regions , 2011, Nature Methods.

[340]  L. Joly,et al.  Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[341]  J. Leprince,et al.  Down-Regulation of GABAA Receptor via Promiscuity with the Vasoactive Peptide Urotensin II Receptor. Potential Involvement in Astrocyte Plasticity , 2012, Regulatory Peptides.

[342]  M. Létourneau,et al.  Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart , 2012, British journal of pharmacology.

[343]  B. Cheung,et al.  Urotensin II: Its Function in Health and Its Role in Disease , 2005, Cardiovascular Drugs and Therapy.

[344]  Ettore Novellino,et al.  Unraveling the active conformation of urotensin II. , 2004, Journal of medicinal chemistry.

[345]  A. Davenport,et al.  Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries , 2004, Peptides.

[346]  B. Jones,et al.  Neurotoxic lesions of the dorsolateral pontomesencephalic tegmentum-cholinergic cell area in the cat. I. Effects upon the cholinergic innervation of the brain , 1988, Brain Research.

[347]  Y. Nakashima,et al.  Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. , 2003, Life sciences.

[348]  S. Bhandari,et al.  Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. , 2007, International journal of cardiology.

[349]  S. Douglas,et al.  Expression of urotensin-II in human coronary atherosclerosis , 2005, Peptides.

[350]  H. Bern,et al.  Specificity of response of intestinal ion transport systems to a pair of natural peptide hormone analogs: somatostatin and urotensin II. , 1983, General and comparative endocrinology.

[351]  A. Schwertani,et al.  A closer look at the role of urotensin II in the metabolic syndrome , 2012, Front. Endocrin..

[352]  David Lovejoy,et al.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor , 1995, Nature.

[353]  H. Vaudry,et al.  Occurrence of two distinct urotensin II-related peptides in zebrafish provides new insight into the evolutionary history of the urotensin II gene family. , 2011, Endocrinology.

[354]  Chao-shu Tang,et al.  Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse , 2009, Regulatory Peptides.

[355]  O. Nayler,et al.  UROTENSIN II MEDIATES ERK1/2 PHOSPHORYLATION AND PROLIFERATION IN GPR14-TRANSFECTED CELL LINES , 2002, Journal of receptor and signal transduction research.

[356]  I. Díaz,et al.  Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation. , 2013, Cardiovascular research.

[357]  S. Sower,et al.  Urotensin II from the river lamprey (Lampetra fluviatilis), the sea lamprey (Petromyzon marinus), and the paddlefish (Polyodon spathula). , 1995, General and comparative endocrinology.

[358]  S. Douglas,et al.  Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. , 2004, Atherosclerosis.

[359]  J. Conlon,et al.  Purification and characterization of urotensin II from the brain of a teleost (trout, Oncorhynchus mykiss) and an elasmobranch (skate, Raja rhina). , 1993, General and comparative endocrinology.

[360]  H. Vaudry,et al.  Identification of a peptide arising from the specific post‐translation processing of secretogranin II , 1991, FEBS letters.

[361]  L. Kriegsfeld,et al.  Identification and characterization of a gonadotropin-inhibitory system in the brains of mammals , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[362]  C. Yulis,et al.  Extraurophyseal distribution of urotensin II immunoreactive neuronal perikarya and their processes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[363]  J. Vaughan,et al.  Characterization of melanin-concentrating hormone from rat hypothalamus. , 1989, Endocrinology.

[364]  H. Sarau,et al.  Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). , 2005, Biochemical pharmacology.

[365]  B. Li,et al.  UII and UT in grouper: cloning and effects on the transcription of hormones related to growth control. , 2013, The Journal of endocrinology.

[366]  P. Molenaar,et al.  Cardiostimulant effects of urotensin‐II in human heart in vitro , 2001, British journal of pharmacology.

[367]  H. Vaudry,et al.  Localization of the urotensin II receptor in the rat central nervous system , 2006, The Journal of comparative neurology.

[368]  Yumiko Saito,et al.  Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction , 1999, Nature Cell Biology.

[369]  N. Aiyar,et al.  Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. , 2000, Journal of cardiovascular pharmacology.

[370]  J. Taylor,et al.  Novel urotensin II (UII) antagonists point to multiple receptor involvement in UII bioactivity , 2000, Regulatory Peptides.

[371]  H. Kobayashi,et al.  Primary structures of multiple forms of urotensin II in the urophysis of the carp, Cyprinus carpio. , 1984, General and comparative endocrinology.

[372]  M. Lew,et al.  Ligand-Supported Purification of the Urotensin-II Receptor , 2010, Molecular Pharmacology.

[373]  S. Oka Immunohistochemical demonstration of urotensins I and II in the caudal neurosecretory system of the white sturgeon, Acipenser transmontanus Richardson , 1989 .

[374]  A. Davenport,et al.  Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1 , 2000, British journal of pharmacology.

[375]  N. Minamino,et al.  Novel fish-derived adrenomedullin in mammals: structure and possible function , 2004, Peptides.

[376]  D. Guidolin,et al.  Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells , 2011, Regulatory Peptides.

[377]  Yves Van de Peer,et al.  2R or not 2R is not the question anymore , 2010, Nature Reviews Genetics.

[378]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[379]  T. Klabunde,et al.  Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.

[380]  C. Yu,et al.  NMR and dynamical simulated annealing studies on the solution conformation of urotensin II. , 1994, Biochimica et biophysica acta.

[381]  Jian Li,et al.  The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting , 2004, Heart and Vessels.

[382]  H. Schiöth,et al.  The Repertoire of G-Protein–Coupled Receptors in Fully Sequenced Genomes , 2005, Molecular Pharmacology.

[383]  Sébastien Arthaud,et al.  Concordant localization of functional urotensin II and urotensin II‐related peptide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle , 2014, The Journal of comparative neurology.

[384]  R. Leduc,et al.  Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. , 2003, The Biochemical journal.

[385]  N. Aiyar,et al.  Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. , 2004, European journal of pharmacology.

[386]  J. Assad,et al.  Urotensin II lowers cytoplasmic free calcium concentration in goby enterocytes: measurements using quin2. , 1986, General and comparative endocrinology.

[387]  D. Behm,et al.  Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma , 2013, Front. Pharmacol..

[388]  O. Lesouhaitier,et al.  In vitro study of the effect of urotensin II on corticosteroid secretion in the frog Rana ridibunda , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[389]  N. Bousette,et al.  Urotensin-II and cardiovascular remodeling , 2008, Peptides.

[390]  S. Douglas,et al.  Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries , 2000, British journal of pharmacology.

[391]  K. Lederis,et al.  Chromatographic separation of urotensins. , 1973, General and comparative endocrinology.

[392]  R. Llinás,et al.  Brainstem control of wakefulness and sleep, Steriade, McCarley. Plenum Press, New York (1990), Price $85.00 , 1991 .

[393]  C. Reynolds,et al.  Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. , 2009, Journal of medicinal chemistry.

[394]  Hong Jiang,et al.  Urotensin II promotes the proliferation of endothelial progenitor cells through p38 and p44/42 MAPK activation. , 2012, Molecular medicine reports.

[395]  J. Ketelslegers,et al.  Raised Plasma Urotensin II in Type 2 Diabetes Patients Is Associated With the Metabolic Syndrome Phenotype , 2010, Journal of clinical hypertension.

[396]  L. Joly,et al.  Chromosomal localization of three somatostatin genes in zebrafish. Evidence that the [Pro2]-somatostatin-14 isoform and cortistatin are encoded by orthologous genes. , 2004, Journal of molecular endocrinology.

[397]  D. Pipeleers,et al.  Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1 , 2003, Diabetologia.

[398]  M. Kikuya,et al.  Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy , 2004, Peptides.

[399]  D. Coy,et al.  Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. , 2002, European journal of pharmacology.

[400]  D. Lambert,et al.  Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[401]  C. Yulis,et al.  Occurrence of an anterior spinal, cerebrospinal fluid-contacting, urotensin II neuronal system in various fish species. , 1988, General and comparative endocrinology.

[402]  Y. Hinokio,et al.  Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese , 2004, Peptides.

[403]  Takeshi Saito,et al.  Involvement of cyclooxygenase-dependent pathway in contraction of isolated ileum by urotensin II , 2005, Peptides.

[404]  E. Novellino,et al.  Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor. , 2014, Journal of medicinal chemistry.

[405]  H. Vaudry,et al.  Behavioral effects of urotensin-II centrally administered in mice , 2005, Psychopharmacology.